NO20074018L - Forebyggelse av trombotiske lidelser med aktive vitamin D forbindelser eller mimetika derav - Google Patents

Forebyggelse av trombotiske lidelser med aktive vitamin D forbindelser eller mimetika derav

Info

Publication number
NO20074018L
NO20074018L NO20074018A NO20074018A NO20074018L NO 20074018 L NO20074018 L NO 20074018L NO 20074018 A NO20074018 A NO 20074018A NO 20074018 A NO20074018 A NO 20074018A NO 20074018 L NO20074018 L NO 20074018L
Authority
NO
Norway
Prior art keywords
compound
active vitamin
thrombotic disorders
animal
mimetics
Prior art date
Application number
NO20074018A
Other languages
English (en)
Norwegian (no)
Inventor
John G Curd
William David Henner
Thomasz M Beer
Bradford S Goodwin
Original Assignee
Novacea Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novacea Inc filed Critical Novacea Inc
Publication of NO20074018L publication Critical patent/NO20074018L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20074018A 2005-01-05 2007-08-02 Forebyggelse av trombotiske lidelser med aktive vitamin D forbindelser eller mimetika derav NO20074018L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64113705P 2005-01-05 2005-01-05
US72113005P 2005-09-28 2005-09-28
PCT/US2006/000181 WO2006074226A2 (en) 2005-01-05 2006-01-05 Prevention of thrombotic disorders with active vitamin d compounds or mimics thereof

Publications (1)

Publication Number Publication Date
NO20074018L true NO20074018L (no) 2007-10-02

Family

ID=36648140

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074018A NO20074018L (no) 2005-01-05 2007-08-02 Forebyggelse av trombotiske lidelser med aktive vitamin D forbindelser eller mimetika derav

Country Status (9)

Country Link
US (1) US20070037779A1 (de)
EP (1) EP1833485A2 (de)
JP (1) JP2008526856A (de)
AU (1) AU2006204091A1 (de)
BR (1) BRPI0606393A2 (de)
CA (1) CA2593982A1 (de)
MX (1) MX2007008227A (de)
NO (1) NO20074018L (de)
WO (1) WO2006074226A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0501186A2 (en) * 2001-12-03 2006-05-29 Novacea Pharmaceutical compositions comprising active vitamin d compounds
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
AU2003295773A1 (en) * 2002-11-21 2004-06-18 Novacea, Inc. Treatment of liver disease with active vitamin d compounds
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
CA2528378A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
CA2528519A1 (en) * 2003-06-11 2005-02-24 Novacea, Inc. Treatment of lung cancer with active vitamin d compounds in combination with other treatments
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
AU2004247109A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc Treatment of cancer with active vitamin D compounds in combination with radiotherapeutic agents and treatments
EP1750728A4 (de) * 2004-05-10 2009-04-29 Novacea Inc Prävention von arterienrestenose mit aktiven vitamin-d-verbindungen
WO2005117542A2 (en) * 2004-05-10 2005-12-15 Novacea, Inc. Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
EP1928471A2 (de) * 2005-09-26 2008-06-11 Novacea, Inc. Prävention und behandlung von gastrointestinalen und blasenstörungen im zusammenhang mit chemotherapie oder strahlentherapie mit aktiven vitamin-d-verbindungen
US20100209536A1 (en) * 2006-09-26 2010-08-19 The Brigham And Women's Hospital, Inc. Methods and Kits for Use in the Treatment and Prevention of Diseases or Conditions of the Immune System or Infectious Diseases
US10716798B2 (en) * 2007-02-21 2020-07-21 The Regents Of The University Of Michigan Compositions and methods for tranquilizing heart muscle
WO2011024208A1 (en) * 2009-08-24 2011-03-03 Colotech A/S Combination dosage form with acetylsalicylic acid, calcitriol and calcium
FI20135701L (fi) * 2013-06-26 2014-12-27 Mas Metabolic Analytical Services Oy Farmaseuttisesti käyttökelpoinen ja turvallinen kombinaatio käytettäväksi merkittävien sairauksien hoidossa
EP3548035A4 (de) 2016-11-30 2020-07-22 Case Western Reserve University Kombinationen von 15-pgdh-inhibitoren mit corticosteroiden und/oder tnf-inhibitoren und verwendungen davon
WO2018145080A1 (en) 2017-02-06 2018-08-09 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
MA49510A (fr) 2017-06-29 2020-05-06 Skyline Biosciences Llc Formulations orales-mucosales d'isotrétinoïne et procédés d'utilisation correspondants

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2208964T3 (es) * 1996-12-10 2004-06-16 G.D. SEARLE & CO. Compuestos de pirrolilo substituidos para el tratamiento de la inflamacion.
CA2326117A1 (en) * 1998-03-27 1999-10-07 Oregon Health Sciences University Vitamin d and its analogs in the treatment of tumors and other hyperproliferative disorders
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
EP1750728A4 (de) * 2004-05-10 2009-04-29 Novacea Inc Prävention von arterienrestenose mit aktiven vitamin-d-verbindungen
US20080069814A1 (en) * 2005-01-05 2008-03-20 Novacea, Inc. Prevention of Thrombotic Disorders with Active Vitamin D Compounds or Mimics Thereof

Also Published As

Publication number Publication date
US20070037779A1 (en) 2007-02-15
MX2007008227A (es) 2007-09-11
CA2593982A1 (en) 2006-07-13
WO2006074226A2 (en) 2006-07-13
JP2008526856A (ja) 2008-07-24
BRPI0606393A2 (pt) 2009-06-23
EP1833485A2 (de) 2007-09-19
WO2006074226A3 (en) 2006-11-16
AU2006204091A1 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
NO20074018L (no) Forebyggelse av trombotiske lidelser med aktive vitamin D forbindelser eller mimetika derav
MA41932B1 (fr) Méthodes de traitement ou de prévention de migraines
MA45811A (fr) Méthodes et compositions de traitement de maladie.
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
BRPI0516132A (pt) compostos, composição destes, método de antagonização de uma ou mais proteases aspárticas e método para tratar ou melhorar um distúrbio mediado por protease aspártica
ECSP17000643A (es) Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol.
EA201892657A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
WO2009039460A3 (en) Co-administration of pimavanserin with other agents
MA40768B1 (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
BRPI0507189A (pt) uso combinado de um agonista de glp-1 e compostos de gastrina
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
WO2015038939A3 (en) Modulators of complement factor b
AU2007247480A8 (en) Pharmaceutical combination comprising 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and an NSAID
NO20023473D0 (no) Sammensetninger for levering av en kortisol antagonist
EA201990425A1 (ru) Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение
NO20075344L (no) Metforminbaserte fremgangsmater og utforminger for behandling av kronisk forstoppelse
AR074313A1 (es) Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo. uso. kit
NO20081863L (no) Forhindring og behandling av gastrointestinal og blaerelidelse assosiert med kemoterapi eller stralingsterapi ved bruk av aktiv vitamin D forbindelse
WO2008005560A3 (en) Prevention of thrombotic disorders with active vitamin d compounds
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
NO20075945L (no) Behandling, prevensjon og ameliorasjon av lungelidelser assosiert med kjemoterapi eller radioterapi med aktive vitamin D sammensetninger eller imitatorer derav
BR112015028788A2 (pt) Peptídeos de angiotensina no tratamento da síndrome de marfan e de distúrbios relacionados
BR112015012497A2 (pt) combinações farmacêuticas
BR112014014805A2 (pt) processos para tratamento e prevenção de constipação induzida por opióide que utilizam composições orais de metilnaltrexona
NO20072851L (no) Hoydose forlenget frigivelses formulering av gepiron

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application